Bristol-Myers Squibb Company (BMY)vsEnbridge Inc (ENB)
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
ENB
Enbridge Inc
$53.59
-0.74%
ENERGY · Cap: $116.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Enbridge Inc generates 34% more annual revenue ($65.19B vs $48.48B). BMY leads profitability with a 15.0% profit margin vs 11.5%. ENB appears more attractively valued with a PEG of 5.73. ENB earns a higher WallStSmart Score of 63/100 (C+).
BMY
Buy60
out of 100
Grade: C+
ENB
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Margin of Safety
+4.6%
Fair Value
$54.02
Current Price
$53.59
$0.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Earnings expanding 294.9% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : ENB
The strongest argument for ENB centers on EPS Growth, Debt/Equity, Market Cap.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : ENB
The primary concerns for ENB are Piotroski F-Score, PEG Ratio, Free Cash Flow.
Key Dynamics to Monitor
ENB carries more volatility with a beta of 0.79 — expect wider price swings.
ENB is growing revenue faster at 5.9% — sustainability is the question.
BMY generates stronger free cash flow (757M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ENB scores higher overall (63/100 vs 60/100). BMY offers better value entry with a 32.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Enbridge Inc
ENERGY · OIL & GAS MIDSTREAM · USA
Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?